tion is negligible if all the processes included are standardized appropriately (2 ) . However, there are few laboratories, if any, that can demonstrate this assumption in real day-today laboratory work. The aim of this study was to quantify the premetrological variation of some biochemical measurements related to the thyroid gland.
Blood specimens were obtained from 20 volunteers from our laboratory staff. For each individual, two almost simultaneous phlebotomies (one in each arm) were performed by two different phlebotomists withdrawing blood from the antecubital veins into evacuated tubes containing no additives but having a gel barrier as serum separator (Becton Dickinson). Each pair of phlebotomists was different for each individual drawn. The tube of blood obtained by the first phlebotomist was sent to the premetrological (receiving and processing) area of our laboratory 30 min after the withdrawal; the tube obtained by the second phlebotomist was sent 30 min after the first tube, to mimic day-to-day differences. The tubes were centrifuged at 1500g for 12 min at 10°C in either of the two centrifuges we have for this purpose. The centrifuged tubes were loaded into the Elecsys 2010 analyzer (Roche Diagnostics) as customary, and the concentrations of thyrotropin (thyroid-stimulating hormone), thyroxine (non-protein bound; also called free T 4 ), and triiodothyronine (also called total T 3 ) in serum were measured. Additionally, all measurements were repeated in one randomly chosen serum sample of each pair.
For each quantity, the analytical variance was calculated as:
Where s G 2 is the analytical variance (within-run metrological variance plus premetrological variance); x and y are the results obtained for different samples from the same individual; and n is the number of individuals.
For each quantity, the metrological within-run variance was calculated as:
Where s Mw 2 is the metrological within-run variance; z and zЈare the replicate results; and n is the number of individuals.
Finally, the premetrological variance was obtained by subtracting s Mw 2 from s G 2 . The CVs corresponding to premetrological variation, calculated using the mean of the 60 measurements done for each quantity, are shown in Table 1 .
For serum thyroxine (non-protein bound) and triiodothyronine, the premetrological variation was negligible; however, for serum thyrotropin, the CV was not null. We conclude that the premetrological CV for thyrotropin measurements should be taken into account when estimating the uncertainty of measurement (3 ) of this analyte. To the Editor: We wish to comment on the case reported recently by Isotalo et al. (1 ) . Two different cardiac troponin I (cTnI) assays were used: the AxSYM (Abbott) and the Opus Plus (Dade Behring). The title of the letter claimed that the cTnI value was normal. This is not consistent with the data presented.
The AxSYM values for cTnI of 1.2 (day 1), 0.8 (day 2), and 1.1 g/L (2 weeks) are not normal. The limit of detection for the AxSYM is 0.3 g/L, with a quoted upper reference limit of 0.4 g/L and an acute myocardial infarction cutoff of 2.0 g/L (2 ). The patient's values fall within the range for detectable and prognostically significant myocardial damage.
The main conclusion that Isotalo et al.
(1 ) make is that the increased cardiac troponin T (cTnT) and creatine kinase MB (CK-MB) concentrations are the result of release from a non-cardiac source related to abnormal expression of these proteins. They did not perform experiments to detect evidence of abnormal cTnT or CK-MB expression in the tumor bi- opsy. Therefore, we fully agree with the authors that their conclusions were "speculative". However, we disagree with their discussion. The authors clearly state that the patient had no biochemical evidence of renal failure. However, they go on to describe, in detail, the findings of three conflicting studies that discuss the issue of skeletal muscle expression of cTnT in uremic patients. The reference to these studies in this case presentation implies that the authors are making an association with the issues of cTnT in patients with renal failure. We believe this to be a tenuous link between their limited study and the subject of skeletal muscle expression of cTnT in renal failure. In addition, we feel that they have either misread or misinterpreted two of the references dealing with this subject that they quote (3, 4 ) . The authors state that "Isoforms of cTnT have been identified in diseased skeletal muscle of chronic renal failure patients by Western blots and highly specific M7 and M11.7 monoclonal antibodies for cTnT (11, 12) . 1 These monoclonal antibodies are the same ones that are used in the [Boehringer Mannheim] secondgeneration cTnT immunoassay".
We disagree with this representation of the findings of the report by Ricchiuti et al. (3 ) . In this report, positive immunoreactive bands were found with M11.7 in Ͻ45% of the samples measured, and Ͻ4.5% were found with M7. The bands did not correspond to the adult cTnT isoform. The authors specifically state that the intact adult cardiac isoform is not detected in skeletal muscle by the antibodies in the Roche assay.
The (5 ) were "unable to demonstrate cTnT mRNA expression in skeletal muscle. . . ". This study clearly demonstrated, with control data, the absence of cTnT mRNA and cTnT protein, using two different experimental formats: Western blot and immunohistochemistry. It should also be stated that the study by Haller et al. (5 ) was in contrast to the two other references (3, 4 ) .
The case presented by Isotalo et al.
(1 ) was potentially interesting but incomplete. If tissue analysis of the tumor had been performed at the protein or molecular level, this would have contributed greatly to the subject of expression of cTnT in non-cardiac tissue.
We also would like to offer a possible explanation as to the causes of these high circulating concentrations of all three markers of myocardial damage. The patient received three cycles of doxorubicin, but the authors did not state the dosages (1 ) . For nearly three decades, reports have appeared that describe the fatal cardiotoxic effects of this drug (6 -8 ) .
Results from human subjects (9 ) and animal models of doxorubicin-induced myopathies (10, 11 ) have shown that these myopathies are directly related to serum concentrations of cTnT. It has even been suggested that monitoring of serum cTnT may be used to assess the severity of doxorubicin-related myocyte damage as an alternative to invasive procedures such as endomyocardial biopsy. The claim by Isotalo et al. (1 ) that the cTnI concentrations were not increased in this patient suggests that cTnI is not a sensitive enough marker to detect drug-induced cardiac damage, whereas CK-MB and cTnT may be.
The authors of the Letter cited above reply:
To the Editor:
We appreciate the interest that Fredericks et al. have shown in our letter (1 ) . As mentioned previously, our patient was a 53-year-old man with metastatic alveolar rhabdomyosarcoma who had increased cardiac markers detected after he developed atypical chest pain while being managed for deep venous thrombosis and inguinal lymph node metastases. In our letter, we erroneously stated that the patient's AxSYM cTnI values were normal when in fact we should have stated that cTnI values were below the cutoff value for acute myocardial infarction (AMI; Յ2.0 g/L). In addition to being below the cutoff for AMI, our patient's cardiac troponin I (cTnI) values were within the 95th percentile of cTnI for non-AMI patients (Յ2.4 g/L), as described by Apple et al. (2 ) .
It is unfortunate that Fredericks et al. have either disregarded or misunderstood our previous discussion regarding cTnT expression and chronic renal failure (1 ). Ricchiuti et al. Skeletal muscle cTnT expression is not restricted to patients with chronic renal disease; it has also been described in the skeletal muscle of patients with Duchenne muscular dystrophy (5 ) . It is clear that Fredericks et al. fail to understand the significance of skeletal muscle cTnT re-expression with respect to our patient. If "diseased" skeletal muscle can re-express an immature, fetal phenotype, as manifested by cTnT re-expression (3 ), it is very reasonable, and in fact logical, to expect that neoplasms with features of skeletal muscle differentiation may also express cTnT isoforms. In addition, anaplastic tumors are genetically unstable, and because of lack of differentiation, they may elaborate proteins that are not usually expressed by their benign tissue counterparts.
With respect to possible doxorubicin cardiac toxicity, our patient had no clinical evidence of cardiomyopathy. Our patient received a total doxorubicin dose of 180 mg/m 2 . Histologic evidence of myocardial toxicity has been identified in endomyocardial biopsies of patients who have been treated with total doxorubicin doses as small as 250 mg/m 2 (6 ) . The risk of doxorubicin-induced cardiomyopathy is dose dependent (7, 8 ) , with cardiomyopathy developing in 30% of patients once total doxorubicin doses of 550 mg/m 2 have been attained (8 ) . It is unlikely that our patient would have ever developed a doxorubicin-induced cardiomyopathy, considering his relatively small total dose of doxorubicin.
In addition to overt cardiomyopathy, it has been suggested that patients treated with doxorubicin may also develop subclinical cardiac toxicity, as evidenced by increased serum troponins, cTnT and cTnI, and cardiac uptake of radiolabeled antimyosin antibodies (7, 9 -11 ) . Lipshultz et al. (9 ) studied 15 children with acute lymphoblastic leukemia who underwent doxorubicin chemotherapy and demonstrated increases in cTnT post anthracycline chemotherapy. None of these patients showed significant increases in creatine kinase (CK), CK-MB, or myoglobin. Anthracycline-treated patients of Missov et al. (11 ) had postanthracycline cTnI increases attributed to subclinical myocyte toxicity, also with no significant increases in CK-MB or myoglobin. Despite the suggestion by Fredericks et al., our patient's sustained increased CK concentrations and his grossly disproportionate increase in CK-MB are inconsistent with both doxorubicininduced cardiac toxicity and acute cardiac ischemia. A CK concentration of 1364 U/L, a CK-MB mass of 1047 g/L, a remarkable CK-MB in-dex of 77, and a cTnT concentration of 2.49 g/L, post tumor radiotherapy, cannot be explained by toxic doxorubicin therapeutic effects, especially considering that these markers were measured 5 months after the patient's last chemotherapy cycle. In addition, our patient had a CK-BB of 25 U/L before his radiotherapy. Ongoing tumor necrosis, especially post radiotherapy, and increased tumor mitotic activity with high neoplastic cell turnover more likely explain these increased values. An association between our patient's biochemical results and doxorubicininduced cardiotoxicity seems inconceivable. In our experience, disproportionate increases in CK-MB in relation to total CK, along with the detection of substantial quantities of CK-BB, cannot be explained by a cardiac source.
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Sensitivity of Assays Designed for the Detection of Disseminated Epithelial Tumor Cells Is Influenced by Cell Separation Methods

To the Editor:
The frequency of detection of disseminated tumor cells in hemopoietic specimens varies among studies (1, 2 ) . For a reliable comparison of results, standardization of detection protocols would be desirable. In addition to concerns about techniques for detection [e.g., reverse transcription-PCR (RT-PCR)], the method for cell isolation may be critical (3, 4 ) .
We examined two methods for cell isolation as applied to three types of specimens before detection of tumor cells by immunocytochemistry or RT-PCR (5 ) .
We analyzed 254 samples consisting of 90 bone marrow aspirates, 104 granulocyte colony-stimulating factor-mobilized stem cell samples harvested at steady-state hemopoiesis, and 60 venous blood samples. Samples were from patients with highrisk breast cancer (n ϭ 237), large bowel cancer (n ϭ 13), gastric cancer (n ϭ 2), ovarian cancer (n ϭ 1), and salivary gland cancer (n ϭ 1). Samples were assigned without conscious bias to nucleated cell separation either by ficoll centrifugation (30 min at 400g without brake) or by ammonium chloride-mediated red cell lysis (RCL). For RCL, samples were diluted 1:10 with RCL buffer (155 mmol/L NH 4 Cl, 10 mmol/L KHCO 3 , 0.1 mmol/L EDTA), incubated for 3-5 min, and centrifuged. Washed cells were counted and subjected to cytospin.
For immunocytochemistry, cells of the isolated fraction were spun onto slides, using a centrifuge from Hettich. A median of two slides (1) (2) (3) were prepared from each sample. Cytokeratin-positive cells were detected with antibody KL1 (Coulter-Immunotech). The median cell count examined was 2 ϫ 10 6 (mean, 1.85 ϫ 10 6 ) with a range from 1 ϫ 10 6 to 1 ϫ 10 7 . Labeled cells were detected by a biotinylated secondary antibody and a streptavidin-alkaline phosphatase procedure. Breast cancer cell lines MCF-7 and MDA-MB453 were used as positive controls, and nucleated cells from non-cancer patients were used as negative controls. Slides were evaluated by light microscopy, and positive cells were counted (2 ) .
For RT-PCR, messenger RNA was measured in 2 ϫ 10 7 nucleated cells from 89 samples (bone marrow, n ϭ 38; leukapheresis, n ϭ 19; and peripheral blood, n ϭ 32) as described previously (4 ) .
Data were analyzed using the computer software WinSTAT (Kalmia). For the comparison of two groups, the Mann-Whitney U-test was used. To compare the tumor cell count detected in different samples, the relative tumor cell count per 10 6 cells examined was calculated.
Tumor cells were detected in more bone marrow samples after RCL compared with ficoll centrifugation (P ϭ 0.045; Table 1 ). For blood samples, a similar but nonsignificant trend was seen (42% vs 31%). Surprisingly, there were no differences between RCL and ficoll centrifugation for leukapheresis samples or for tumor cell detection by CK19 RT-PCR.
Similarly, the number of tumor cells identified/10 6 cells was higher after RCL for all 254 samples (P ϭ 0.05) and for bone marrow aspirations (P ϭ 0.05). For venous blood samples and apheresis samples, nonsignificant trends were seen ( Table  1) .
The present data are derived from 
